In Cellular Cancer Markers leading pathologists and physicians review today's most promising cellular cancer markers, an important emerging class of prognostic markers that can be used in the clinical evaluation of cancer patients. The markers reviewed have been chosen because they are biologically relevant to the growth of cells and possess an accurate and reproducible assay for detection. They also are predictors of tumor behavior, are useful in making clinical decisions, and are cost effective.
Cellular Cancer Markers provides a status report for markers of tumor cell activation, proliferation, and longevity that makes possible an informed judgment regarding the value of many newly proposed tumor markers. It also offers insight into the latest approaches to diagnosing cancer and an appreciation of how these marker-based tests can clarify the prognosis of cancer.
Rezensionen / Stimmen
The editors should be commended for attempting an extensive compilation of information on cancer markers...-New England Journal of Medicine
Reihe
Auflage
Softcover reprint of the original 1st ed. 1995
Sprache
Verlagsort
Zielgruppe
Für Beruf und Forschung
Professional/practitioner
Illustrationen
Maße
Höhe: 229 mm
Breite: 152 mm
Dicke: 27 mm
Gewicht
ISBN-13
978-1-61737-000-7 (9781617370007)
DOI
10.1007/978-1-4757-2381-6
Schweitzer Klassifikation
Ch. 1. Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer.- Ch. 2. ras Proto-Oncogene Activation in Human Malignancy.- Ch. 3. C-myc as a Tumor Marker for Primary Human Cancers.- Ch. 4. p53 in Human Cancer.- Ch. 5. Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies.- Ch. 6. Genetic Alterations in Colon Cancer.- Ch. 7. Genetic Changes in Breast Cancer.- Ch. 8. Genetic Alterations in Lung Cancer.- Ch. 9. Wilms Tumor-Susceptibility Loci.- Ch. 10. Non-Hodgkin's Lymphomas.- Ch. 11. Phenotypic Expression of Hodgkin's Disease: Biologic, Immunologic, and Functional Properties of Reed-Sternberg Cells.- Ch. 12. Melanoma Markers.- Ch. 13. Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma.- Ch. 14. P-Glycoproteins in Tumors.- Ch. 15. Genetically Engineered Antitumor Monoclonal Antibodies.- Ch. 16. Targeting Antisense Oligonucleotide Chemotherapy to the Type I Regulatory Subunit of cAMP-Dependent Protein Kinase.- Ch. 17. Summary and Perspective: Assessing Test Effectiveness-The Identification of Good Tumor Markers.
